Submit Manuscript  

Article Details

Comparison of Antibody Immune Responses to Different HIV-1 Envelope Glycoprotein Mutants

[ Vol. 15 , Issue. 1 ]


Jian-Dong Liu, Li Ren, Bin Ju, Wei Song, Xiang-Yang Ge, Kun-Xue Hong, Ying Liu, Wei Xu, Yan-Ling Hao and Yi-Ming Shao   Pages 23 - 30 ( 8 )


Background: The identification of immunogens is crucial for human immunodeficiency virus type 1 (HIV-1) vaccine development. In our previous study, we demonstrated that HIV-1 envelope glycoprotein mutants based on the equine infectious anemia virus (EIAV) attenuated vaccine enhance immunogenicity, both for DNA immunization alone and as a combined DNA prime-vaccinia boost immunization. An RV144 clinical trial has demonstrated that an envelope protein boost may provide some degree of protection against HIV-1 infection.

Methods: In order to explore the antibody immune responses to two HIV-1 envelope glycoprotein mutants based on the EIAV vaccine and wild-type envelope glycoprotein, mice and guinea pigs were immunized using a DNA prime-protein boost immunization strategy.

Results: The result showed, compared with wild-type gp140, gp140 2M (which contained 2 sites amino acid mutations) and gp140 5M (which contained 5 sites amino acid mutations) increased envspecific IgG and IgG3 binding antibody titers. Gp140 2M resulted in a slight improvement in the neutralizing antibody response against sensitive HIV-1 isolates compared with gp140.

Conclusion: These findings have implications for HIV-1 vaccine development based on the HIV-1 CN54 envelope glycoprotein.


HIV-1, mutant, vaccine, IgG subclass, prime-boost immunization.


State Key Laboratory for Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, 155 Changbai Road, Changping District, Beijing 102206

Graphical Abstract:

Read Full-Text article